Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

por Phillips, D C, Xiao, Y, Lam, L T, Litvinovich, E, Roberts-Rapp, L, Souers, A J, Leverson, J D
Publicado 2015

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

por Phillips, D C, Xiao, Y, Lam, L T, Litvinovich, E, Roberts-Rapp, L, Souers, A J, Leverson, J D
Publicado 2016

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

por Touzeau, C, Dousset, C, Le Gouill, S, Sampath, D, Leverson, J D, Souers, A J, Maïga, S, Béné, M C, Moreau, P, Pellat-Deceunynck, C, Amiot, M
Publicado 2014

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

por Leverson, J D, Zhang, H, Chen, J, Tahir, S K, Phillips, D C, Xue, J, Nimmer, P, Jin, S, Smith, M, Xiao, Y, Kovar, P, Tanaka, A, Bruncko, M, Sheppard, G S, Wang, L, Gierke, S, Kategaya, L, Anderson, D J, Wong, C, Eastham-Anderson, J, Ludlam, M J C, Sampath, D, Fairbrother, W J, Wertz, I, Rosenberg, S H, Tse, C, Elmore, S W, Souers, A J
Publicado 2015